Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

Shots: Japan’s MHLW has received NDA for conditional approval of avacincaptad pegol (ACP) to treat geographic atrophy (GA) secondary to AMD Submission was backed by the P-II/III (GATHER1) & P-III (GATHER2) trials assessing safety & efficacy of ACP (2mg, Q1M, intravitreal) in pts with GA secondary to AMD Data from both trials showed reduced…

ByRidhi RastogiFebruary 5, 2025

VIEWPOINTS

Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

Shots: At ASCO 2024, Astellas Pharma presented 16 abstracts across several types of cancers with unmet medical needs Today at PharmaShots, we have Ahsan Arozullah Sr. VP, Head of Oncology Development, shedding light on the advancement Astellas’ oncology portfolio for urothelial carcinoma, gastric cancer, and prostate cancer Ahsan talks about the presented results from studies…

BySaurabh ChaubeySeptember 16, 2024

TOP 20

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots: Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncology The advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more…

ByPrince GiriSeptember 8, 2022

TOP 20

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology- Hematology and multiple diseases but due to a drastic increase in the immune disorders- Immunology segment has been widely spared across the globe. In the top 20…

ByPrince GiriAugust 9, 2019

Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

Contact US

OUR INFORMATION

FOLLW US

Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

FOLLW US

Sign Up to Our Newsletter